Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market (Indication - Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia; End user - Hospitals, Clinics, Home Care) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL1930
  • Published On : Oct 2018
  • No. of Pages : 232
  • Category : Pharmaceutical

Section 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

Section 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology

Section 3. Executive Summary
3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2. Market Share Analysis, by Region, 2017
3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map

Section 4. Market Overview
4.1. Indication Overview
4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators

Section 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
       5.2.1. Rise in prevalence of autoimmune disorders
       5.2.2. Increase in global geriatric population
       5.2.3. Growing usage in off-label indications
       5.2.4. Improved technology for production and purification methods
       5.2.5. Favorable government initiatives and approvals
       5.2.6. Increase in health care spending & improving health care infrastructure
       5.2.7. Rise in incidence of hematological, neurological disorders
5.3. Restraints
       5.3.1. High cost of treatment
       5.3.2. Chronic side effects
       5.3.3. Supply demand gaps
       5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5. Opportunities
       5.5.1. Application in newer indications
       5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.6. Key Trends
5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
5.8. Value Chain Analysis
5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook

Section 6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1. Key Findings
6.2. Introduction
6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
       6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
       6.4.2. Primary Humoral Immunodeficiency
       6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
       6.4.4. Guillain-Barre Syndrome
       6.4.5. Myasthenia Gravis
       6.4.6. Multifocal Motor Neuropathy (MMN)
       6.4.7. Kawasaki Disease
       6.4.8. Hypogammaglobulinemia
       6.4.9. Chronic Lymphocytic Leukemia
       6.4.10. Others
6.5. Market Attractiveness Analysis, by Indication
6.6. Key Trends

Section 7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
       7.4.1. Hospitals
       7.4.2. Clinics
       7.4.3. Home Care
7.5. Market Attractiveness Analysis, by End-user
7.6. Key Trends

Section 8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4. Market Attractiveness Analysis, by Region

Section 9. North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Market Analysis, by Indication
       9.3.1. Market Value Share Analysis, by Indication
       9.3.2. Market Size (US$ Mn) Forecast, by Indication
                9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                9.3.2.2. Primary Humoral Immunodeficiency
                9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
                9.3.2.4. Guillain-Barre Syndrome
                9.3.2.5. Myasthenia Gravis
                9.3.2.6. Multifocal Motor Neuropathy (MMN)
                9.3.2.7. Kawasaki Disease
                9.3.2.8. Hypogammaglobulinemia
                9.3.2.9. Chronic Lymphocytic Leukemia
                9.3.2.10. Others
9.4. Market Analysis, by End-user
       9.4.1. Market Value Share Analysis, by End-user
       9.4.2. Market Size (US$ Mn) Forecast, by End-user
                9.4.2.1. Hospitals
                9.4.2.2. Clinics
                9.4.2.3. Home Care
9.5. Market Analysis, by Country
       9.5.1. Market Value Share Analysis, by Country
       9.5.2. Market Size (US$ Mn) Forecast, by Country, 2018–2026
                9.5.2.1. U.S.
                9.5.2.2. Canada
9.6. Market Attractiveness Analysis
       9.6.1. By Indication
       9.6.2. By End-user
       9.6.3. By Country
9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis
       9.7.1. Market Size (US$ Mn) Forecast, by Indication
                9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                9.7.1.2. Primary Humoral Immunodeficiency
                9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                9.7.1.4. Guillain-Barre Syndrome
                9.7.1.5. Myasthenia Gravis
                9.7.1.6. Multifocal Motor Neuropathy (MMN)
                9.7.1.7. Kawasaki Disease
                9.7.1.8. Hypogammaglobulinemia
                9.7.1.9. Chronic Lymphocytic Leukemia
                9.7.1.10. Others
       9.7.2. Market Size (US$ Mn) Forecast, by End-user
                9.7.2.1. Hospitals
                9.7.2.2. Clinics
                9.7.2.3. Home Care Settings
9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis
       9.8.1. Market Size (US$ Mn) Forecast, by Indication
                9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                9.8.1.2. Primary Humoral Immunodeficiency
                9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                9.8.1.4. Guillain-Barre Syndrome
                9.8.1.5. Myasthenia Gravis
                9.8.1.6. Multifocal Motor Neuropathy (MMN)
                9.8.1.7. Kawasaki Disease
                9.8.1.8. Hypogammaglobulinemia
                9.8.1.9. Chronic Lymphocytic Leukemia
                9.8.1.10. Others
       9.8.2. Market Size (US$ Mn) Forecast, by End-user
                9.8.2.1. Hospitals
                9.8.2.2. Clinics
                9.8.2.3. Home Care Settings

Section 10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Market Analysis, by Indication
       10.3.1. Market Value Share Analysis, by Indication
       10.3.2. Market Size (US$ Mn) Forecast, by Indication
                10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.3.2.2. Primary Humoral Immunodeficiency
                10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.3.2.4. Guillain-Barre Syndrome
                10.3.2.5. Myasthenia Gravis
                10.3.2.6. Multifocal Motor Neuropathy (MMN)
                10.3.2.7. Kawasaki Disease
                10.3.2.8. Hypogammaglobulinemia
                10.3.2.9. Chronic Lymphocytic Leukemia
                10.3.2.10. Others
10.4. Market Analysis, by End-user
       10.4.1. Market Value Share Analysis, by End-user
       10.4.2. Market Size (US$ Mn) Forecast, by End-user
                10.4.2.1. Hospitals
                10.4.2.2. Clinics
                10.4.2.3. Home Care
10.5. Market Analysis, by Country/Sub-region
       10.5.1. Market Value Share Analysis, by Country
       10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
                10.5.2.1. U.K.
                10.5.2.2. Germany
                10.5.2.3. France
                10.5.2.4. Spain
                10.5.2.5. Italy
                10.5.2.6. Rest of Europe
10.6. Market Attractiveness Analysis
       10.6.1. By Indication
       10.6.2. By End-user
       10.6.3. By Country/Sub-region
10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis
       10.7.1. Market Size (US$ Mn) Forecast, by Indication
                10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.7.1.2. Primary Humoral Immunodeficiency
                10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.7.1.4. Guillain-Barre Syndrome
                10.7.1.5. Myasthenia Gravis
                10.7.1.6. Multifocal Motor Neuropathy (MMN)
                10.7.1.7. Kawasaki Disease
                10.7.1.8. Hypogammaglobulinemia
                10.7.1.9. Chronic Lymphocytic Leukemia
                10.7.1.10. Others
       10.7.2. Market Size (US$ Mn) Forecast, by End-user
                10.7.2.1. Hospitals
                10.7.2.2. Clinics
                10.7.2.3. Home Care Settings
10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis
       10.8.1. Market Size (US$ Mn) Forecast, by Indication
                10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.8.1.2. Primary Humoral Immunodeficiency
                10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.8.1.4. Guillain-Barre Syndrome
                10.8.1.5. Myasthenia Gravis
                10.8.1.6. Multifocal Motor Neuropathy (MMN)
                10.8.1.7. Kawasaki Disease
                10.8.1.8. Hypogammaglobulinemia
                10.8.1.9. Chronic Lymphocytic Leukemia
                10.8.1.10. Others
       10.8.2. Market Size (US$ Mn) Forecast, by End-user
                10.8.2.1. Hospitals
                10.8.2.2. Clinics
                10.8.2.3. Home Care Settings
10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis
       10.9.1. Market Size (US$ Mn) Forecast, by Indication
                10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.9.1.2. Primary Humoral Immunodeficiency
                10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.9.1.4. Guillain-Barre Syndrome
                10.9.1.5. Myasthenia Gravis
                10.9.1.6. Multifocal Motor Neuropathy (MMN)
                10.9.1.7. Kawasaki Disease
                10.9.1.8. Hypogammaglobulinemia
                10.9.1.9. Chronic Lymphocytic Leukemia
                10.9.1.10. Others
       10.9.2. Market Size (US$ Mn) Forecast, by End-user
                10.9.2.1. Hospitals
                10.9.2.2. Clinics
                10.9.2.3. Home Care Settings
10.10 Spain Intravenous Immunoglobulin (IVIG) Market Analysis
       10.10.1. Market Size (US$ Mn) Forecast, by Indication
                10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.10.1.2. Primary Humoral Immunodeficiency
                10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.10.1.4. Guillain-Barre Syndrome
                10.10.1.5. Myasthenia Gravis
                10.10.1.6. Multifocal Motor Neuropathy (MMN)
                10.10.1.7. Kawasaki Disease
                10.10.1.8. Hypogammaglobulinemia
                10.10.1.9. Chronic Lymphocytic Leukemia
                10.10.1.10. Others
       10.10.2. Market Size (US$ Mn) Forecast, by End-user
                10.10.2.1. Hospitals
                10.10.2.2. Clinics
                10.10.2.3. Home Care Settings
10.11 Italy Intravenous Immunoglobulin (IVIG) Market Analysis
       10.11.1. Market Size (US$ Mn) Forecast, by Indication
                10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.11.1.2. Primary Humoral Immunodeficiency
                10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.11.1.4. Guillain-Barre Syndrome
                10.11.1.5. Myasthenia Gravis
                10.11.1.6. Multifocal Motor Neuropathy (MMN)
                10.11.1.7. Kawasaki Disease
                10.11.1.8. Hypogammaglobulinemia
                10.11.1.9. Chronic Lymphocytic Leukemia
                10.11.1.10. Others
       10.11.2. Market Size (US$ Mn) Forecast, by End-user
                10.11.2.1. Hospitals
                10.11.2.2. Clinics
                10.11.2.3. Home Care Settings
10.12 Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis
       10.12.1. Market Size (US$ Mn) Forecast, by Indication
                10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                10.12.1.2. Primary Humoral Immunodeficiency
                10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                10.12.1.4. Guillain-Barre Syndrome
                10.12.1.5. Myasthenia Gravis
                10.12.1.6. Multifocal Motor Neuropathy (MMN)
                10.12.1.7. Kawasaki Disease
                10.12.1.8. Hypogammaglobulinemia
                10.12.1.9. Chronic Lymphocytic Leukemia
                10.12.1.10. Others
       10.12.2. Market Size (US$ Mn) Forecast, by End-user
                10.12.2.1. Hospitals
                10.12.2.2. Clinics
                10.12.2.3. Home Care Settings

Section 11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Market Analysis, by Indication
       11.3.1. Market Value Share Analysis, by Indication
       11.3.2. Market Size (US$ Mn) Forecast, by Indication
                11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.3.2.2. Primary Humoral Immunodeficiency
                11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.3.2.4. Guillain-Barre Syndrome
                11.3.2.5. Myasthenia Gravis
                11.3.2.6. Multifocal Motor Neuropathy (MMN)
                11.3.2.7. Kawasaki Disease
                11.3.2.8. Hypogammaglobulinemia
                11.3.2.9. Chronic Lymphocytic Leukemia
                11.3.2.10. Others
11.4. Market Analysis, by End-user
       11.4.1. Market Value Share Analysis, by End-user
       11.4.2. Market Size (US$ Mn) Forecast, by End-user
                11.4.2.1. Hospitals
                11.4.2.2. Clinics
                11.4.2.3. Home Care
11.5. Market Analysis, by Country/Sub-region
       11.5.1. Market Value Share Analysis, by Country
       11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
                11.5.2.1. China
                11.5.2.2. Japan
                11.5.2.3. Australia
                11.5.2.4. India
                11.5.2.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
       11.6.1. By Indication
       11.6.2. By End-user
       11.6.3. By Country/Sub-region
11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis
       11.7.1. Market Size (US$ Mn) Forecast, by Indication
                11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.7.1.2. Primary Humoral Immunodeficiency
                11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.7.1.4. Guillain-Barre Syndrome
                11.7.1.5. Myasthenia Gravis
                11.7.1.6. Multifocal Motor Neuropathy (MMN)
                11.7.1.7. Kawasaki Disease
                11.7.1.8. Hypogammaglobulinemia
                11.7.1.9. Chronic Lymphocytic Leukemia
                11.7.1.10. Others
       11.7.2. Market Size (US$ Mn) Forecast, by End-user
                11.7.2.1. Hospitals
                11.7.2.2. Clinics
                11.7.2.3. Home Care Settings
11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis
       11.8.1. Market Size (US$ Mn) Forecast, by Indication
                11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.8.1.2. Primary Humoral Immunodeficiency
                11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.8.1.4. Guillain-Barre Syndrome
                11.8.1.5. Myasthenia Gravis
                11.8.1.6. Multifocal Motor Neuropathy (MMN)
                11.8.1.7. Kawasaki Disease
                11.8.1.8. Hypogammaglobulinemia
                11.8.1.9. Chronic Lymphocytic Leukemia
                11.8.1.10. Others
       11.8.2. Market Size (US$ Mn) Forecast, by End-user
                11.8.2.1. Hospitals
                11.8.2.2. Clinics
                11.8.2.3. Home Care Settings
11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis
       11.9.1. Market Size (US$ Mn) Forecast, by Indication
                11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.9.1.2. Primary Humoral Immunodeficiency
                11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.9.1.4. Guillain-Barre Syndrome
                11.9.1.5. Myasthenia Gravis
                11.9.1.6. Multifocal Motor Neuropathy (MMN)
                11.9.1.7. Kawasaki Disease
                11.9.1.8. Hypogammaglobulinemia
                11.9.1.9. Chronic Lymphocytic Leukemia
                11.9.1.10. Others
       11.9.2. Market Size (US$ Mn) Forecast, by End-user
                11.9.2.1. Hospitals
                11.9.2.2. Clinics
                11.9.2.3. Home Care Settings
11.10 India Intravenous Immunoglobulin (IVIG) Market Analysis
       11.10.1. Market Size (US$ Mn) Forecast, by Indication
                11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.10.1.2. Primary Humoral Immunodeficiency
                11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.10.1.4. Guillain-Barre Syndrome
                11.10.1.5. Myasthenia Gravis
                11.10.1.6. Multifocal Motor Neuropathy (MMN)
                11.10.1.7. Kawasaki Disease
                11.10.1.8. Hypogammaglobulinemia
                11.10.1.9. Chronic Lymphocytic Leukemia
                11.10.1.10. Others
       11.10.2. Market Size (US$ Mn) Forecast, by End-user
                11.10.2.1. Hospitals
                11.10.2.2. Clinics
                11.10.2.3. Home Care Settings
11.11 Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
       11.11.1. Market Size (US$ Mn) Forecast, by Indication
                11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                11.11.1.2. Primary Humoral Immunodeficiency
                11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                11.11.1.4. Guillain-Barre Syndrome
                11.11.1.5. Myasthenia Gravis
                11.11.1.6. Multifocal Motor Neuropathy (MMN)
                11.11.1.7. Kawasaki Disease
                11.11.1.8. Hypogammaglobulinemia
                11.11.1.9. Chronic Lymphocytic Leukemia
                11.11.1.10. Others
       11.11.2. Market Size (US$ Mn) Forecast, by End-user
                11.11.2.1. Hospitals
                11.11.2.2. Clinics
                11.11.2.3. Home Care Settings

Section 12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Market Analysis, by Indication
       12.3.1. Market Value Share Analysis, by Indication
       12.3.2. Market Size (US$ Mn) Forecast, by Indication
                12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                12.3.2.2. Primary Humoral Immunodeficiency
                12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
                12.3.2.4. Guillain-Barre Syndrome
                12.3.2.5. Myasthenia Gravis
                12.3.2.6. Multifocal Motor Neuropathy (MMN)
                12.3.2.7. Kawasaki Disease
                12.3.2.8. Hypogammaglobulinemia
                12.3.2.9. Chronic Lymphocytic Leukemia
                12.3.2.10. Others
12.4. Market Analysis, by End-user
       12.4.1. Market Value Share Analysis, by End-user
       12.4.2. Market Size (US$ Mn) Forecast, by End-user
                12.4.2.1. Hospitals
                12.4.2.2. Clinics
                12.4.2.3. Home Care
12.5. Market Analysis, by Country/Sub-region
       12.5.1. Market Value Share Analysis, by Country/Sub-region
       12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
                12.5.2.1. Brazil
                12.5.2.2. Mexico
                12.5.2.3. Rest of LATAM
12.6. Market Attractiveness Analysis
       12.6.1. By Indication
       12.6.2. By End-user
       12.6.3. By Country/Sub-region
12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis
       12.7.1. Market Size (US$ Mn) Forecast, by Indication
                12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                12.7.1.2. Primary Humoral Immunodeficiency
                12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                12.7.1.4. Guillain-Barre Syndrome
                12.7.1.5. Myasthenia Gravis
                12.7.1.6. Multifocal Motor Neuropathy (MMN)
                12.7.1.7. Kawasaki Disease
                12.7.1.8. Hypogammaglobulinemia
                12.7.1.9. Chronic Lymphocytic Leukemia
                12.7.1.10. Others
       12.7.2. Market Size (US$ Mn) Forecast, by End-user
                12.7.2.1. Hospitals
                12.7.2.2. Clinics
                12.7.2.3. Home Care Settings
12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis
       12.8.1. Market Size (US$ Mn) Forecast, by Indication
                12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                12.8.1.2. Primary Humoral Immunodeficiency
                12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                12.8.1.4. Guillain-Barre Syndrome
                12.8.1.5. Myasthenia Gravis
                12.8.1.6. Multifocal Motor Neuropathy (MMN)
                12.8.1.7. Kawasaki Disease
                12.8.1.8. Hypogammaglobulinemia
                12.8.1.9. Chronic Lymphocytic Leukemia
                12.8.1.10. Others
       12.8.2. Market Size (US$ Mn) Forecast, by End-user
                12.8.2.1. Hospitals
                12.8.2.2. Clinics
                12.8.2.3. Home Care Settings
12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
       12.9.1. Market Size (US$ Mn) Forecast, by Indication
                12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                12.9.1.2. Primary Humoral Immunodeficiency
                12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                12.9.1.4. Guillain-Barre Syndrome
                12.9.1.5. Myasthenia Gravis
                12.9.1.6. Multifocal Motor Neuropathy (MMN)
                12.9.1.7. Kawasaki Disease
                12.9.1.8. Hypogammaglobulinemia
                12.9.1.9. Chronic Lymphocytic Leukemia
                12.9.1.10. Others
       12.9.2. Market Size (US$ Mn) Forecast, by End-user
                12.9.2.1. Hospitals
                12.9.2.2. Clinics
                12.9.2.3. Home Care Settings

Section 13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Market Analysis, by Indication
       13.3.1. Market Value Share Analysis, by Indication
       13.3.2. Market Size (US$ Mn) Forecast, by Indication
                13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                13.3.2.2. Primary Humoral Immunodeficiency
                13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
                13.3.2.4. Guillain-Barre Syndrome
                13.3.2.5. Myasthenia Gravis
                13.3.2.6. Multifocal Motor Neuropathy (MMN)
                13.3.2.7. Kawasaki Disease
                13.3.2.8. Hypogammaglobulinemia
                13.3.2.9. Chronic Lymphocytic Leukemia
                13.3.2.10. Others
13.4. Market Analysis, by End-user
       13.4.1. Market Value Share Analysis, by End-user
       13.4.2. Market Size (US$ Mn) Forecast, by End-user
                13.4.2.1. Hospitals
                13.4.2.2. Clinics
                13.4.2.3. Home Care
13.5. Market Analysis, by Country/Sub-region
       13.5.1. Market Value Share Analysis, by Country/Sub-region
       13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
                13.5.2.1. GCC Countries
                13.5.2.2. South Africa
                13.5.2.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
       13.6.1. By Indication
       13.6.2. By End-user
       13.6.3. By Country/Sub-region
13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis
       13.7.1. Market Size (US$ Mn) Forecast, by Indication
                13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                13.7.1.2. Primary Humoral Immunodeficiency
                13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                13.7.1.4. Guillain-Barre Syndrome
                13.7.1.5. Myasthenia Gravis
                13.7.1.6. Multifocal Motor Neuropathy (MMN)
                13.7.1.7. Kawasaki Disease
                13.7.1.8. Hypogammaglobulinemia
                13.7.1.9. Chronic Lymphocytic Leukemia
                13.7.1.10. Others
       13.7.2. Market Size (US$ Mn) Forecast, by End-user
                13.7.2.1. Hospitals
                13.7.2.2. Clinics
                13.7.2.3. Home Care Settings
13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis
       13.8.1. Market Size (US$ Mn) Forecast, by Indication
                13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                13.8.1.2. Primary Humoral Immunodeficiency
                13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                13.8.1.4. Guillain-Barre Syndrome
                13.8.1.5. Myasthenia Gravis
                13.8.1.6. Multifocal Motor Neuropathy (MMN)
                13.8.1.7. Kawasaki Disease
                13.8.1.8. Hypogammaglobulinemia
                13.8.1.9. Chronic Lymphocytic Leukemia
                13.8.1.10. Others
       13.8.2. Market Size (US$ Mn) Forecast, by End-user
                13.8.2.1. Hospitals
                13.8.2.2. Clinics
                13.8.2.3. Home Care Settings
13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
       13.9.1. Market Size (US$ Mn) Forecast, by Indication
                13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
                13.9.1.2. Primary Humoral Immunodeficiency
                13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
                13.9.1.4. Guillain-Barre Syndrome
                13.9.1.5. Myasthenia Gravis
                13.9.1.6. Multifocal Motor Neuropathy (MMN)
                13.9.1.7. Kawasaki Disease
                13.9.1.8. Hypogammaglobulinemia
                13.9.1.9. Chronic Lymphocytic Leukemia
                13.9.1.10. Others
       13.9.2. Market Size (US$ Mn) Forecast, by End-user
                13.9.2.1. Hospitals
                13.9.2.2. Clinics
                13.9.2.3. Home Care Settings

Section 14. Company Profiles
14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2017)
14.2. Competition Matrix
14.3. Company Profiles
       14.3.1. Baxalta Incorporated

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.2. Biotest AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.3. China Biologic Products, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.4. CSL Behring LLC

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.5. Grifols S.A.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.6. Kedrion S.p.A.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.7. LFB Biomedicaments S.A.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.8. Octapharma AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

       14.3.9. Sanquin Plasma Products B.V.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Financial Overview
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

List of Tables

Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2018–2026
Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 07: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 08: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 09: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 10: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 11: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 12: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 13: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 14: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 15: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 16: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 17: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 18: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 19: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 20: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 21: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 22: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 23: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 24: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 25: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 26: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 27: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 28: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 29: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 30: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 31: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 32: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 33: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 34: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 35: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 36: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 37: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 38: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 39: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2026
Table 40: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 41: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 42: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 43: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 44: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 45: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 46: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 47: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 48: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2016–2026
Table 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 50: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 51: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 52: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 53: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 54: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026
Table 55: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 56: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2018–2026

List of Figures

Figure 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
Figure 02: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2018 and 2026
Figure 03: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2016–2026
Figure 04: Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2016–2026
Figure 05: Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2016–2026
Figure 06: Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2016–2026
Figure 07: Global Myasthenia Gravis Market Revenue, US$ Mn, 2016–2026
Figure 08: Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2016–2026
Figure 09: Global Kawasaki Disease Market Revenue, US$ Mn, 2016–2026
Figure 10: Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2016–2026
Figure 11: Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2016–2026
Figure 12: Global Other Indications Market Revenue, US$ Mn, 2016–2026
Figure 13: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
Figure 14: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2018 and 2026
Figure 15: Global Hospitals Market Revenue, US$ Mn, 
Figure 16: Global Clinics Market Revenue, US$ Mn,
Figure 17: Global home care Market Revenue, US$ Mn, 2016–2026
Figure 18: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
Figure 19: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2018 and 2026
Figure 20: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
Figure 21: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2018–2026
Figure 22: North America Market Attractiveness Analysis, by Country
Figure 23: North America Market Value Share Analysis, by Indication, 2018 and 2026
Figure 24: North America Market Value Share Analysis, by End-user, 2018 and 2026
Figure 25: North America Market Value Share Analysis, by Country, 2018 and 2026
Figure 26: North America Market Attractiveness Analysis, by Indication 
Figure 27: North America Market Attractiveness Analysis, by End-user
Figure 28: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2018–2026
Figure 29: Europe Market Attractiveness Analysis, by Country/Sub-region
Figure 30: Europe Market Value Share Analysis, by Indication, 2018 and 2026
Figure 31: Europe Market Value Share Analysis, by End-user, 2018 and 2026
Figure 32: Europe Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 33: Europe Market Attractiveness Analysis, by Indication
Figure 34: Europe Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
Figure 36: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
Figure 37: Asia Pacific Market Value Share Analysis, by Indication, 2018 and 2026
Figure 38: Asia Pacific Market Value Share Analysis, by End-user, 2018 and 2026
Figure 39: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 40: Asia Pacific Market Attractiveness Analysis, by Indication
Figure 41: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 42: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
Figure 43: Latin America Market Attractiveness Analysis, by Country/Sub-region
Figure 44: Latin America Market Value Share Analysis, by Indication, 2018 and 2026
Figure 45: Latin America Market Value Share Analysis, by End-user, 2018 and 2026
Figure 46: Latin America Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 47: Latin America Market Attractiveness Analysis, by Indication
Figure 48: Latin America Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
Figure 50: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region
Figure 51: Middle East & Africa Market Value Share Analysis, by Indication, 2018 and 2026
Figure 52: Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2026
Figure 53: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 54: Middle East & Africa Market Attractiveness Analysis, by Indication
Figure 55: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 56: Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2017)

.